Value proposition

Pioneering First-in-Class Treatments for Thromboinflammatory Diseases

Founded on pioneering research by Riitta Lassila and associates at the Wihuri Research Institute in Helsinki, Aplagon is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapeutics for thromboinflammatory diseases, addressing critical unmet medical needs in vascular medicine.

Its lead therapeutic, APAC, a heparin proteoglycan mimetic, is a dual AntiPlatelet and AntiCoagulant (APAC) with unique antithrombotic and anti-inflammatory properties. Designed to specifically target vascular injury sites, APAC provides localized, long-term action while minimizing systemic exposure.

The company’s clinical pipeline focuses on addressing thromboinflammatory conditions, with lead indications in arteriovenous fistula (AVF) maturation failure for hemodialysis patients and chronic limb threatening ischemia (CLTI) to prevent amputations and major cardiovascular events.


Thromboinflammatory Diseases, Antithrombotic Therapies, Cardiovascular Disease Research, Clinical-Stage Biopharmaceuticals, APAC Therapeutics, Antiplatelet and Anticoagulant Research, Vascular Inflammation, Hemodialysis Access Failure Prevention, Critical Limb Ischemia Treatment, Peripheral Arterial Disease, Vascular Surgery Innovations, Drug Development, Biopharmaceutical Research, Clinical Trials, Biotechnology Innovations, Life Sciences, Medical Research, Pharmaceutical Development, and Healthcare Solutions